Aaron Seth Kesselheim

Aaron Seth Kesselheim, MD, JD, MPH

Professor of Medicine
Member, HMS Center for Bioethics

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Dr. Kesselheim received his medical and legal training at the University of Pennsylvania and his M.P.H. at the Harvard School of Public Health. Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. At the HMS Center for Bioethics, he co-teaches a course on health policy, law, and bioethics and organizes the monthly policy and ethics consortium.

Publications View
Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Authors: Authors: Bendicksen L, Rome BN, Avorn J, Kesselheim AS.
Milbank Q
View full abstract on Pubmed
Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic.
Authors: Authors: Rome BN, Avorn J, Kesselheim AS.
J Gen Intern Med
View full abstract on Pubmed
Raising Medicaid Rebates For Drugs With Accelerated Approval.
Authors: Authors: Rome BN, Kesselheim AS.
Health Aff (Millwood)
View full abstract on Pubmed
Public-sector Contributions to Novel Biologic Drugs.
Authors: Authors: Nayak RK, Lee CC, Avorn J, Kesselheim AS.
JAMA Intern Med
View full abstract on Pubmed
Discovery and Development of Pregabalin (Lyrica): The Role of Public Funding.
Authors: Authors: Barenie R, Darrow J, Avorn J, Kesselheim AS.
Neurology
View full abstract on Pubmed
A Court Decision on "Skinny Labeling": Another Challenge for Less Expensive Drugs.
Authors: Authors: Walsh BS, Bloomfield D, Kesselheim AS.
JAMA
View full abstract on Pubmed
Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms.
Authors: Authors: Gyawali B, Ross JS, Kesselheim AS.
JAMA Intern Med
View full abstract on Pubmed
Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
Authors: Authors: Lee CC, Najafzadeh M, Kesselheim AS, Sarpatwari A.
Clin Pharmacol Ther
View full abstract on Pubmed
Variations in Generic Combination Opioid Use Across State Medicaid Programs.
Authors: Authors: Lee CC, Kesselheim AS, Avorn J.
J Gen Intern Med
View full abstract on Pubmed
Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed.
Authors: Authors: Pregelj L, Hine DC, Kesselheim AS, Darrow JJ.
Clin Pharmacol Ther
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
Boston, MA 02120